
NYSE:PG
This summary was created by AI, based on 11 opinions in the last 12 months.
Procter & Gamble (PG) is currently facing a challenging economic landscape, with experts indicating that consumer products are experiencing difficulties. The company has been described as a defensive stock due to its strong brand portfolio and consistent dividend payments near 3%. Despite a decline in stock performance, with a noted drop of 14.4% over the past year, some analysts believe it is an opportune time to invest, albeit gradually, given its quality and dividend aristocrat status. However, there are concerns about low earnings growth, rising input costs, and a persistently cautious consumer sentiment. While PG maintains strong margins, its revenue growth has been slow, prompting mixed sentiments regarding its immediate future, especially as it approaches an earnings report amidst a weak economy.
PG vs. JNJ JNJ valuation of 16-17x earnings is cheaper than PG. JNJ has 3 areas: medical devices, healthcare, pharma. PG is just consumer products, trading at 23x earnings. More opportunity in JNJ, with a caveat on the talc lawsuits. JNJ's medical device side should do well post-Covid. Dividends similar in the 2.5% range.
He owns Unilever for their global exposure. P&G beat earnings but their revenues were down. It's trading like a growth stock even though it isn't. They have been coming out with new products. There is progress in grooming products but their baby care has been struggling. He also doesn't like their compliance and ethics. They reward 10% of their float to their executives and not helping employees. They are also make polluting products like Pampers and Swiffers.